To our knowledge, little information is currently available on effects of AZD8055 or other mTOR inhibitors under hypoxic conditions, with the exception of BEZ235 which has been shown to sensitize hypoxic breast and prostate cancer cells to radiation [26, 27]. This evidence concerns the gene MTOR and prostate carcinoma.